Histogen Inc. (HSTO): Price and Financial Metrics

Histogen Inc. (HSTO): $0.51

0.00 (0.88%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add HSTO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#122 of 381

in industry

HSTO Price/Volume Stats

Current price $0.51 52-week high $1.64
Prev. close $0.51 52-week low $0.36
Day low $0.50 Volume 23,400
Day high $0.52 Avg. volume 425,159
50-day MA $0.67 Dividend yield N/A
200-day MA $0.88 Market Cap 2.20M

HSTO Stock Price Chart Interactive Chart >

HSTO Stock Summary

  • HSTO has a higher market value than merely 0.88% of US stocks; more precisely, its current market capitalization is $2,336,652.
  • HSTO's price/sales ratio is 122.98; that's higher than the P/S ratio of 98.05% of US stocks.
  • Revenue growth over the past 12 months for HISTOGEN INC comes in at -99.56%, a number that bests merely 0.69% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to HSTO, based on their financial statements, market capitalization, and price volatility, are AMST, NURO, NTGR, IRBT, and CTSO.
  • HSTO's SEC filings can be seen here. And to visit HISTOGEN INC's official web site, go to www.histogeninc.com.

HSTO Valuation Summary

  • HSTO's price/sales ratio is 121.1; this is 2927.5% higher than that of the median Healthcare stock.
  • Over the past 124 months, HSTO's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for HSTO.

Stock Date P/S P/B P/E EV/EBIT
HSTO 2023-09-22 121.1 0.2 -0.2 0.1
HSTO 2023-09-21 110.5 0.2 -0.2 0.1
HSTO 2023-09-20 110.5 0.2 -0.2 0.1
HSTO 2023-09-19 89.5 0.2 -0.1 0.1
HSTO 2023-09-18 147.4 0.3 -0.2 0.0
HSTO 2023-09-15 152.6 0.3 -0.2 0.0

HSTO Growth Metrics

    The year over year price growth rate now stands at -81.55%.
  • The 2 year revenue growth rate now stands at -70.35%.
  • Its 4 year net cashflow from operations growth rate is now at -161.39%.
Over the past 30 months, HSTO's revenue has gone down $10,923,000.

The table below shows HSTO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.77 -9.962 -11.28
2022-06-30 4.356 -11.399 -11.525
2022-03-31 4.356 -11.265 -11.353
2021-12-31 1.032 -14.532 -14.95
2021-09-30 1.505 -15.888 -15.323
2021-06-30 1.409 -15.751 -14.731

HSTO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HSTO has a Quality Grade of D, ranking ahead of 11.54% of graded US stocks.
  • HSTO's asset turnover comes in at 0.064 -- ranking 308th of 681 Pharmaceutical Products stocks.
  • PLXP, AGTC, and LPTX are the stocks whose asset turnover ratios are most correlated with HSTO.

The table below shows HSTO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.064 0.403 -1.400
2021-03-31 0.080 0.385 -2.095
2020-12-31 0.126 0.530 -2.520
2020-09-30 0.062 0.633 -4.218
2020-09-30 0.062 0.633 -4.218
2020-06-30 0.190 0.978 -6.396

HSTO Price Target

For more insight on analysts targets of HSTO, see our HSTO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.00 Average Broker Recommendation 1.25 (Strong Buy)

Histogen Inc. (HSTO) Company Bio


Histogen Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. It offers human multipotent cell conditioned media (CCM); human extracellular matrix (hECM); and hair stimulating complex (HSC). The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. Histogen Inc. is headquartered San Diego, California.


HSTO Latest News Stream


Event/Time News Detail
Loading, please wait...

HSTO Latest Social Stream


Loading social stream, please wait...

View Full HSTO Social Stream

Latest HSTO News From Around the Web

Below are the latest news stories about HISTOGEN INC that investors may wish to consider to help them evaluate HSTO as an investment opportunity.

Histogen to Explore Strategic Alternatives

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs

Yahoo | July 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are a hot topic with traders on Thursday as we go over the shares seeing the biggest movements this morning.

William White on InvestorPlace | June 8, 2023

Histogen Reports First Quarter 2023 Results and Provides Business Update

Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Signed Exclusive Intellectual Property License Agreement with Johns Hopkins University Steven J. Mento Ph.D. Appointed President and CEO SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potentia

Yahoo | May 11, 2023

Histogen Announces Online Publication in the Journal of Investigative Dermatology

Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today

Yahoo | April 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders need to know about this morning!

William White on InvestorPlace | April 5, 2023

Read More 'HSTO' Stories Here

HSTO Price Returns

1-mo -25.11%
3-mo N/A
6-mo -55.65%
1-year -62.22%
3-year -98.38%
5-year -99.95%
YTD -38.55%
2022 -87.53%
2021 -56.11%
2020 -81.05%
2019 -76.88%
2018 -62.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!